Board Meeting3 Aug 2026, 04:14 pm
GSK Pharma Board Approves Q1 FY27 Unaudited Results; Management Changes
AI Summary
GlaxoSmithKline Pharmaceuticals Ltd announced the outcome of its Board Meeting held on August 3, 2026. The Board approved the Un-audited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. Key management changes were also noted: Mr. Subesh Williams stepped down as Non-Executive Director, and Ms. Karine J F Natland is appointed as Non-Executive Director. Additionally, Mr. Bhushan Akshikar has been re-appointed as Managing Director for a term of two years effective December 1, 2026. The company reported Revenue from operations of ₹92,442 Lakhs and Other income of ₹6,163 Lakhs for the quarter ended June 30, 2026.
Key Highlights
- GSK Pharma declared Q1 FY27 unaudited financial results.
- Revenue from operations for Q1 FY27 stood at ₹92,442 Lakhs.
- Mr. Subesh Williams resigned as Non-Executive Director.
- Ms. Karine J F Natland appointed as Non-Executive Director.
- Mr. Bhushan Akshikar re-appointed as Managing Director for two years.
Price Impact
More from GLAXO